VIVO Cannabis(TM) Enters Into New Supply Agreement With Medipharm Labs Australia

This Post Was Syndicated Under License Via QuoteMedia

VIVO <a title class="aalmanual" target="_blank" href="https://v.gotanka.com/869ea410-c449-4a26-bab5-867674e5a61d" rel="noopener">Cannabis</a>™ Enters Into New Supply Agreement With Medipharm Labs Australia

Canada NewsWire

NAPANEE, ON, June 19, 2020 /CNW/ – VIVO Cannabis Inc. (TSX: VIVO), (OTCQX: VVCIF) (“VIVO” or the “Company“) today announced that its subsidiary, Beacon Medical Australia Pty. Ltd. (“Beacon Medical Australia“), entered into an agreement with MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia“), a subsidiary of MediPharm Labs Corp. (TSX: LABS) (“MediPharm Labs“), whereby MediPharm Labs Australia will supply pharmaceutical-quality (GMP certified), formulated cannabis oil products to Beacon Medical Australia to sell into the Australian market.

Logo: VIVO Cannabis Inc. (CNW Group/VIVO Cannabis Inc.)

“VIVO’s international efforts remain focused on the emerging Australian and German markets and we continue to seek out partnerships with organizations that have proven track records,” said Barry Fishman, CEO of VIVO. “For this reason, we are thrilled to be working with MediPharm Labs to leverage their GMP production capabilities to accelerate our Australian market presence. We are confident this will allow us to continue to provide our Australian patients with the medical-grade products they have come to expect from the Beacon Medical™ brand.”

“Just weeks after MediPharm Labs Australia was granted GMP Certification, we’re pleased to announce this agreement that underscores the burgeoning demand for our specialized skills and rapid success in converting our opportunity pipeline into tangible, revenue-generating business,” said Warren Everitt, CEO, Asia Pacific, MediPharm Labs. “We are excited to be working with VIVO to bring high quality products to medical consumers across Australia and other emerging markets.”

MediPharm Labs is a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products. Under the agreement with Beacon Medical Australia, which has an initial one-year term subject to renewal, MediPharm Labs Australia will supply a full range of GMP-certified, formulated CBD and THC cannabis oil products to Beacon Medical Australia for further distribution under its own branding.

About VIVO Cannabis

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities with proprietary plant-growing technology in Hope, British Columbia and Napanee, Ontario. VIVO has a collection of premium brands, each targeting different customer segments, including Canna Farms™, Beacon Medical™, Fireside™, Fireside-X™, Lumina™ and Canadian Bud Collection™. The Company is expanding its production capabilities and distribution network. Harvest Medicine, VIVO’s patient-centric, scalable network of medical cannabis clinics, has serviced over 100,000 patient visits. VIVO is pursuing several partnership and product development opportunities and is focusing its international efforts on Germany and Australia. The Company has a healthy balance sheet and is well-positioned to accelerate its path to profitability. For more information visit: www.vivocannabis.com

Disclaimer for Forward-Looking Information

Certain statements in this news release are forward-looking statements, which are statements that are not purely historical, including statements regarding the beliefs, plans, expectations or intentions of VIVO and its management regarding the future. Forward-looking statements in this news release include statements that the agreement with MediPharm will accelerate VIVO’s Australian market presence, the range and quality of products VIVO will obtain from MediPharm, and other benefits it expects to derive from the agreement. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Company may not derive the expected benefits from the MediPharm agreement; that the administrative processes necessary to terminate the Plan may take longer than expected; that the COVID-19 pandemic may last longer and have a more significant impact on the Company’s operations, financing abilities, the Canadian cannabis industry, or the global economy generally, than currently expected; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are urged to consider these factors, and the more extensive risk factors included in the Company’s management’s discussion and analysis for the three months ended March 31, 2020, which is available on SEDAR, carefully in evaluating the forward-looking statements contained in this news release, and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements. The forward-looking statements in this news release are made as of the date hereof and the Company disclaims any intent or obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

SOURCE VIVO Cannabis Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2020/19/c0148.html

VIVO Investor Relations, Michael Bumby, Chief Financial Officer, +1 416-848-9839, [email protected] CNW Group 2020

If You Liked This Article Click To Share

.mobile_tx{display: none;}
#ax1x{
font-size: 1.1em;
font-weight: bold;
line-height: 1.5;
clear:both;
margin: 0px 0px 20px 1% !important;
min-height: 4.5em;
text-transform: uppercase;
padding: .25em 0 10px 0;
position: relative;
width: 98%;
float: left;
}
.next-pg {
height: 85px !important;
width: 100%;
border-top-left-radius: 3px;
border-bottom-left-radius: 3px;
background-color: #e5192c ;
background-image: url(‘/wp-content/themes/mh-magazine/images/global-after.png’) !important;
background-repeat: no-repeat;
background-position: right center;
background-size: auto 100%;
overflow: hidden;
box-sizing: border-box;
margin-bottom: 0px;
margin-top: 10px;
position: relative;
padding-left: 100px;
}
.next-pg::before {
width: 45px !important;
height: 85px !important;
display: block;
content: “”;
width: 32px;
height: 64px;
background-image: url(‘/wp-content/themes/mh-magazine/images/global-before.png’) !important;
background-repeat: no-repeat;
background-position: right center;
background-size: auto 100%;
position: absolute;
left: -4px;
top: 0px;
}
.action-txt {
text-transform: uppercase;
margin: 12px;
line-height: 61px;
text-align: left;
font-size: 36px;
background-repeat: no-repeat;
background-position: right center;
background-size: 26px 18px;
color: #FFF;
float: left;
font-weight: bold;
font-family: “Open Sans”,sans-serif !important;
width: 78%;
display: inline-block;
text-align: center;
}
@media (max-width: 768px){
.mobile_tx{display: block;}
.desktop_tx{display: none;}
.pps-slider-nav .pps-next {
text-align: center;
position: static;
padding: 5px 20px;
float: left;
width: 100%;
box-sizing: border-box;
}
.pps-next .next-article-page {
padding-left: 0;
float: left;
margin: 0;
}
.next-article-page .action-txt {
padding-left: 0!important;
text-align: center;
width: 87%;
box-sizing: border-box;
font-size: 26px;
background: 0 0;
text-align: center;
}
#ax1x {
padding: .25em 0!important;
min-height: 2.3em;
width: 100% !important;
margin: 0px !important;
margin-bottom: 15px !important;
padding-bottom: 0!important;
}
}
@media (max-width: 500px){
.next-article-page .action-txt{
width: 75%;
}
}

Latest posts